Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Allergan

Status and phase: Completed; Phase 3; Phase 2

Conditions: Ocular Hypertension

Treatments: Drug: bimatoprost

Study type: Interventional

Funder types: Industry

Identifiers

NCT00300443

192024-031

Details and patient eligibility

About

The purpose of this study is to assess the safety and efficacy of bimatoprost in patients with glaucoma or ocular hypertension

Enrollment: 561 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of glaucoma or ocular hypertension in both eyes
• Patient requires IOP-lowering drug in both eyes

Exclusion criteria

• Uncontrolled medical conditions
• Ocular seasonal allergies within the past 2 years

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind